Insider Selling: FibroGen, Inc (FGEN) Director Sells $813,960.00 in Stock

FibroGen, Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total value of $813,960.00. Following the transaction, the director now owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of FibroGen, Inc (FGEN) opened at $46.87 on Monday. FibroGen, Inc has a 1 year low of $19.25 and a 1 year high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

ILLEGAL ACTIVITY WARNING: “Insider Selling: FibroGen, Inc (FGEN) Director Sells $813,960.00 in Stock” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/20/insider-selling-fibrogen-inc-fgen-director-sells-813960-00-in-stock.html.

Several research analysts have recently weighed in on the company. Leerink Swann reiterated an “outperform” rating and set a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair restated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Citigroup Inc. raised their target price on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus raised their target price on FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.67.

Hedge funds have recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of FibroGen in the 2nd quarter worth approximately $128,000. Oppenheimer Asset Management Inc. raised its stake in FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 696 shares during the last quarter. BBR Partners LLC purchased a new position in shares of FibroGen in the third quarter worth $299,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of FibroGen in the third quarter worth $299,000. Hedge funds and other institutional investors own 50.82% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply